Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
In 2025, the company reported a +4.31% YoY revenue growth, driven by its specialty segment momentum: Austedo ($2.21B) continues to be the key growth driver with strong uptake in movement disorders, Copaxone ($255M) continues its decline due to generic competition, while UZEDY ($191M) is gaining early traction as a long-acting injectable for schizophrenia, reflecting Tevas push into differentiated CNS therapies
Cell metabolism , 36 (1), 130-143.
How Long Do Dental Fillers for Receding Gums Last
Tips for successful weight management with weight loss injections While GLP-1s have been hyped as miracle cures, there is no magic wand for weight loss
The calorie deficit that initially caused weight loss may no longer be large enough to continue producing the same results
